Non-peptide GLP-1 agonist
What a GLP-1 receptor agonist actually does: which receptors it reaches, how it slows gastric emptying, and the satiety pathway it runs through.
What is Non-peptide GLP-1 agonist?
A small organic molecule that switches on the GLP-1 receptor without being built from a peptide chain, so it survives stomach acid intact and needs none of the absorption scaffolding oral peptides require.
Foundayo (orforglipron) was the first FDA-approved one, in April 2026.
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Non-peptide GLP-1 agonist comes up on this site
Drug pages
Connected terms
Other terms under Mechanism
- GIP receptor
- Dual agonist
- Gastric emptying
- Food noise
- Triple agonist
- Amylin
- GLP-1 tachyphylaxis
- A1C (glycated hemoglobin)
- MASH / MASLD
- TBWL (Total Body Weight Loss)
- C-peptide
- eGFR (estimated glomerular filtration rate)
- Visceral adipose tissue (VAT)
- AHI (apnea-hypopnea index)
- SNAC (oral semaglutide absorption enhancer)
Where the evidence lives
- Foundayo drug overview
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers